-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Recent -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
mesenchymal -X- _ B-Intervention
stem -X- _ I-Intervention
cells -X- _ I-Intervention
( -X- _ I-Intervention
MSCs -X- _ I-Intervention
) -X- _ I-Intervention
modulate -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
and -X- _ O
reduce -X- _ O
lung -X- _ O
injury -X- _ O
in -X- _ O
animal -X- _ O
models. -X- _ O
Currently -X- _ O
, -X- _ O
no -X- _ O
clinical -X- _ O
studies -X- _ O
of -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
MSCs -X- _ B-Intervention
in -X- _ O
acute -X- _ B-Patient
respiratory -X- _ I-Patient
distress -X- _ I-Patient
syndrome -X- _ I-Patient
( -X- _ I-Patient
ARDS -X- _ I-Patient
) -X- _ I-Patient
exist. -X- _ O
The -X- _ O
objectives -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
were -X- _ O
first -X- _ O
to -X- _ O
examine -X- _ O
the -X- _ O
possible -X- _ O
adverse -X- _ O
events -X- _ O
after -X- _ O
systemic -X- _ O
administration -X- _ O
of -X- _ O
allogeneic -X- _ B-Intervention
adipose-derived -X- _ I-Intervention
MSCs -X- _ I-Intervention
in -X- _ O
ARDS -X- _ B-Patient
patients -X- _ I-Patient
and -X- _ O
second -X- _ O
to -X- _ O
determine -X- _ O
potential -X- _ O
efficacy -X- _ O
of -X- _ O
MSCs -X- _ O
on -X- _ O
ARDS. -X- _ O
METHODS -X- _ O
: -X- _ O
Twelve -X- _ B-Patient
adult -X- _ I-Patient
patients -X- _ I-Patient
meeting -X- _ O
the -X- _ O
Berlin -X- _ O
definition -X- _ O
of -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
with -X- _ O
a -X- _ O
PaO -X- _ O
( -X- _ O
2 -X- _ O
) -X- _ O
/ -X- _ O
FiO -X- _ O
( -X- _ O
2 -X- _ O
) -X- _ O
ratio -X- _ O
of -X- _ O
< -X- _ O
200 -X- _ O
were -X- _ O
randomized -X- _ O
to -X- _ O
receive -X- _ B-Intervention
allogeneic -X- _ I-Intervention
adipose-derived -X- _ I-Intervention
MSCs -X- _ I-Intervention
or -X- _ O
placebo -X- _ B-Comparison
in -X- _ O
a -X- _ O
1:1 -X- _ O
fashion. -X- _ O
Patients -X- _ O
received -X- _ O
one -X- _ O
intravenous -X- _ O
dose -X- _ O
of -X- _ O
1 -X- _ O
Ã— -X- _ O
10 -X- _ O
( -X- _ O
6 -X- _ O
) -X- _ O
cells -X- _ O
/ -X- _ O
kg -X- _ O
of -X- _ O
body -X- _ O
weight -X- _ O
or -X- _ O
saline. -X- _ O
Possible -X- _ O
side -X- _ O
effects -X- _ O
were -X- _ O
monitored -X- _ O
after -X- _ O
treatment. -X- _ O
Acute -X- _ O
lung -X- _ O
injury -X- _ O
biomarkers -X- _ O
, -X- _ O
including -X- _ O
IL-6 -X- _ O
, -X- _ O
IL-8 -X- _ O
and -X- _ O
surfactant -X- _ O
protein -X- _ O
D -X- _ O
( -X- _ O
SP-D -X- _ O
) -X- _ O
, -X- _ O
were -X- _ O
examined -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
MSCs -X- _ O
on -X- _ O
lung -X- _ O
injury -X- _ O
and -X- _ O
inflammation. -X- _ O
RESULTS -X- _ O
: -X- _ O
There -X- _ B-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
infusion -X- _ I-Outcome
toxicities -X- _ I-Outcome
or -X- _ I-Outcome
serious -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
related -X- _ I-Outcome
to -X- _ I-Outcome
MSCs -X- _ I-Outcome
administration -X- _ I-Outcome
and -X- _ I-Outcome
there -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
overall -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
two -X- _ I-Outcome
groups. -X- _ I-Outcome
Length -X- _ I-Outcome
of -X- _ I-Outcome
hospital -X- _ I-Outcome
stay -X- _ I-Outcome
, -X- _ I-Outcome
ventilator-free -X- _ I-Outcome
days -X- _ I-Outcome
and -X- _ I-Outcome
ICU-free -X- _ I-Outcome
days -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
28 -X- _ I-Outcome
after -X- _ I-Outcome
treatment -X- _ I-Outcome
were -X- _ I-Outcome
similar. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
changes -X- _ I-Outcome
in -X- _ I-Outcome
biomarkers -X- _ I-Outcome
examined -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
placebo -X- _ I-Outcome
group. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
MSCs -X- _ I-Outcome
group -X- _ I-Outcome
, -X- _ I-Outcome
serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
levels -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
5 -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
0 -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.027 -X- _ I-Outcome
) -X- _ I-Outcome
while -X- _ I-Outcome
the -X- _ I-Outcome
changes -X- _ I-Outcome
in -X- _ I-Outcome
IL-8 -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
significant. -X- _ I-Outcome
The -X- _ I-Outcome
IL-6 -X- _ I-Outcome
levels -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
5 -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
trend -X- _ I-Outcome
towards -X- _ I-Outcome
lower -X- _ I-Outcome
levels -X- _ I-Outcome
as -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
day -X- _ I-Outcome
0 -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
this -X- _ I-Outcome
trend -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
statistically -X- _ I-Outcome
significant -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.06 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Administration -X- _ B-Outcome
of -X- _ I-Outcome
allogeneic -X- _ I-Outcome
adipose-derived -X- _ I-Outcome
MSCs -X- _ I-Outcome
appears -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
safe -X- _ I-Outcome
and -X- _ I-Outcome
feasible -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
ARDS. -X- _ I-Outcome
However -X- _ O
, -X- _ O
the -X- _ O
clinical -X- _ O
effect -X- _ O
with -X- _ O
the -X- _ O
doses -X- _ O
of -X- _ O
MSCs -X- _ O
used -X- _ O
is -X- _ O
weak -X- _ O
, -X- _ O
and -X- _ O
further -X- _ O
optimization -X- _ O
of -X- _ O
this -X- _ O
strategy -X- _ O
will -X- _ O
probably -X- _ O
be -X- _ O
required -X- _ O
to -X- _ O
reach -X- _ O
the -X- _ O
goal -X- _ O
of -X- _ O
reduced -X- _ O
alveolar -X- _ O
epithelial -X- _ O
injury -X- _ O
in -X- _ O
ARDS. -X- _ O
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
Clinical -X- _ O
trials.gov -X- _ O
, -X- _ O
NCT01902082 -X- _ O

